Following the initiation of antiretroviral therapy, most HIV-infected individuals experience significant weight gain. It was originally thought to result from reduced energy consumption associated with suppression of overt virus replication. However, recent evidence suggests that is not simply a back to normal phenomenon. Indeed, a differential influence on weight has been noticed for distinct antiretroviral drugs, some of which may produce abnormal body weight gain and metabolic disturbances. Treatment with integrase inhibitors in particular leads to significant increases in body mass index. By contrast, protease inhibitors might protect from undesirable weight gain. Ultimately, the development of overweight and obesity in an aging HIV population may increase the risk of cardiovascular events and should be prevented. In this scenario, the differential influence on weight gain using distinct antiretroviral agents might provide an opportunity for personalized medicine, adapting the most convenient drug regimen to each patient.

中文翻译：

---

使用不同抗逆转录病毒药物的 HIV 感染者体重增加。

在开始抗逆转录病毒治疗后，大多数 HIV 感染者的体重都会显着增加。它最初被认为是由于与明显病毒复制的抑制相关的能量消耗减少所致。然而，最近的证据表明，这不仅仅是恢复正常的现象。事实上，已经注意到不同抗逆转录病毒药物对体重的不同影响，其中一些可能会导致体重异常增加和代谢紊乱。特别是用整合酶抑制剂治疗导致体重指数显着增加。相比之下，蛋白酶抑制剂可能会防止体重增加。最终，艾滋病毒老龄化人群中超重和肥胖的发展可能会增加心血管事件的风险，应该加以预防。在这种情况下，